A Study of ONO-7475 in Patients With Acute Leukemias

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 26, 2017

Primary Completion Date

December 1, 2022

Study Completion Date

January 20, 2023

Conditions
Acute LeukemiaMyelodysplastic Syndromes
Interventions
DRUG

ONO-7475 3mg once daily

Part A initial dose level

DRUG

ONO-7475 6mg once daily

Part A 2nd dose level

DRUG

ONO-7475 10mg once daily

Part A 3rd dose level

DRUG

ONO-7475 6mg + Venetoclax (70-400mg)

Part D ONO-7475 + Venetoclax Combination

Trial Locations (16)

10021

Weill Medical College of Cornell University, New York

19107

Thomas Jefferson University, Philadelphia

27157

Wake Forest University, Winston-Salem

29425

Medical University of South Carolina - Hollins Cancer Center, Charleston

30322

The Winship Cancer Institute Emory University, Atlanta

30912

Augusta University Medical Center, Augusta

32224

Mayo Clinic - Jacksonville, Jacksonville

32610

University of Florida (UF) - Shands Cancer Center, Gainesville

40207

Norton Cancer Institute, Louisville

43210

The Ohio State University (OSU), Columbus

48109

University of Michigan, Ann Arbor

77030

MD Anderson Cancer Center, Houston

84112

University of Utah - Huntsman Cancer Institute, Salt Lake City

90033

University of Southern California, Los Angeles

90095

University of California, Los Angeles

06510

Yale University School of Medicine - Yale Cancer Center, North Haven

Sponsors
All Listed Sponsors
lead

Ono Pharmaceutical Co. Ltd

INDUSTRY